Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
- F. Barlesi
- , A. Scherpereel
- , V. Gorbunova
- , R. Gervais
- , A. Vikström
- , C. Chouaid
- , A. Chella
- , J. H. Kim
- , M. J. Ahn
- , M. Reck
- , A. Pazzola
- , H. T. Kim
- , J. G. Aerts
- , C. Morando
- , A. Loundou
- , H. J.M. Groen
- , A. Rittmeyer
- Aix-Marseille Université
- Hôpital Claude Huriez
- N N Blokhin Russian Cancer Research Centre
- Centre Georges-François Leclerc
- Lungkliniken
- Sorbonne Université
- University of Pisa
- Yonsei University
- Sungkyunkwan University
- Grosshansdorf
- University Hospital of Sassari
- National Cancer Center
- Amphia Hospital
- Assistance publique - Hôpitaux de Marseille
- University of Groningen
- Lungenfachklinik Immenhausen
Research output: Contribution to journal › Article › peer-review
166
Link opens in a new tab
Scopus
citations